HIST1H2BB and MAGI2 Methylation and Somatic Mutations as Precision Medicine Biomarkers for Diagnosis and Prognosis of High-grade Serous Ovarian Cancer.

doi:10.1158/1940-6207.CAPR-19-0412

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

HIST1H2BB and MAGI2 Methylation and Somatic Mutations as Precision Medicine Biomarkers for Diagnosis and Prognosis of High-grade Serous Ovarian Cancer.

Cancer prevention research (Philadelphia, Pa.) - 1 Sept 2020

Valle Blanca L, Rodriguez-Torres Sebastian, Kuhn Elisabetta, Díaz-Montes Teresa, Parrilla-Castellar Edgardo, Lawson Fahcina P, Folawiyo Oluwasina, Ili-Gangas Carmen, Brebi-Mieville Priscilla, Eshleman James R, Herman James, Shih Ie-Ming, Sidransky David, Guerrero-Preston Rafael

Abstract excerpt

Molecular alterations that contribute to long-term (LT) and short-term (ST) survival in ovarian high-grade serous carcinoma (HGSC) may be used as precision medicine biomarkers. DNA promoter methylation is an early event in tumorigenesis, which can be detected in blood and urine, making it a feasible companion biomarker to somatic mutations for early detection and targeted treatment workflows. We compared the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cystadenocarcinoma, Serous

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Decitabine

Share to Epithelium

Share to Fallopian Tubes

Share to Guanylate Kinases

Share to Hydroxamic Acids

Share to Ovary

Share to Precision Medicine

Source

Open in PubMed Open full text

Identifiers

PMID: 32581010
DOI: 10.1158/1940-6207.CAPR-19-0412
PMCID: PMC8082233

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HIST1H2BB and MAGI2 Methylation and Somatic Mutations as Precision Medicine Biomarkers for Diagnosis and Prognosis of High-grade Serous Ovarian Cancer.PMID 32581010Read ↗

Genomic Analyses of Germline and Somatic Variation in High-Grade Serous Ovarian CancerSemantic proximity Read ↗

Differential DNA methylation in high-grade serous ovarian cancer (HGSOC) is associated with tumor behaviorSemantic proximity Read ↗

Exome sequencing identifies<i>HELB</i>as a novel susceptibility gene for non-mucinous, non-high-grade-serous epithelial ovarian cancerSemantic proximity Read ↗

Molecular analysis for ovarian cancer detection in patient-friendly samplesSemantic proximity Read ↗

Methylomic Analysis of Ovarian Cancers Identifies Tumor-Specific Alterations Readily Detectable in Early Precursor LesionsSemantic proximity Read ↗

DNA Methylation and Transcriptomic Features are Preserved Throughout Disease Recurrence and Chemoresistance in High Grade Serous Ovarian CancersSemantic proximity Read ↗

DNA methylation landscapes of matched primary and recurrent high grade serous ovarian cancers are preserved throughout disease progression and chemoresistanceSemantic proximity Read ↗

DNA methylation and transcriptomic features are preserved throughout disease recurrence and chemoresistance in high grade serous ovarian cancersSemantic proximity Read ↗

Genome-scale screen for DNA methylation-based detection markers for ovarian cancer.Semantic proximity Read ↗

Intra-tumor heterogeneity of MLH1 promoter methylation revealed by deep single molecule bisulfite sequencing.Semantic proximity Read ↗

Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer.Semantic proximity Read ↗

Exome sequencing identifies HELB as a novel susceptibility gene for non-mucinous, non-high-grade-serous epithelial ovarian cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.